Last updated: July 26, 2026
Jackson, M.D. v. NuVasive, Inc. (1:21-cv-00053): Litigation Summary, Patent Claims, and Business Impact
Jackson, M.D. v. NuVasive, Inc., No. 1:21-cv-00053 is pending in federal court and centers on patent infringement allegations against NuVasive, Inc. The case timing (filed 2021) places it in the post-registration window where claim construction, noninfringement/invalidity positions, and any dismissal or settlement posture typically drive downstream freedom-to-operate decisions. However, the record needed to produce a complete, accurate litigation summary tied to asserted patents, claim scope, procedural milestones, and outcomes is not available in the provided input.
What patents are asserted in Jackson, M.D. v. NuVasive, Inc. 1:21-cv-00053?
No asserted-patent list, patent numbers, claim lists, or allegations are included in the provided information. Without the complaint’s “Patents-In-Suit” section, the analysis cannot identify which patents protect which product features (device components, methods, software, or data workflows) or whether infringement theories are direct, induced, or willful.
What are the “Patents-in-Suit” and who is the patent owner?
The case caption identifies the defendant as NuVasive, Inc. It does not provide the patent owner, assignee, or asserted portfolio details needed to map ownership and licensing leverage.
What technology is implicated (implants, navigation, software, instruments)?
No description of the allegedly infringing NuVasive products or claimed features is provided, so no technical claim mapping can be performed.
What is the procedural history of 1:21-cv-00053 (motions, scheduling, claim construction)?
No docket milestones are included (for example: Rule 12 motions, transfer decisions, claim construction order dates, summary judgment, Daubert rulings, trial date updates, or settlement notices). Without docket events, a litigation timeline and posture assessment cannot be produced.
When was the case filed and what stage is it in?
The only date signal provided is “1:21,” consistent with filing in 2021, but no actual filing date, service date, or last docket entry is provided. Stage assessment requires docket references.
Are there related PTAB or ITC proceedings?
No information is provided on inter partes review, post-grant review, ex parte reexamination, or ITC filings that frequently affect claim scope and settlement leverage.
Who challenged whom: Jackson, M.D. v. NuVasive infringement theories and relief sought?
The input provides no complaint allegations, no jurisdictional basis, and no relief request terms (injunction, damages, attorney fees, enhanced damages, costs). A complete litigation analysis cannot be produced without those pleadings.
Is the theory direct infringement, induced infringement, or willful infringement?
No theories or mens rea allegations are provided.
What remedies are requested (injunction vs. damages)?
No remedy details are provided.
What does NuVasive’s defense look like (invalidity, noninfringement, exhaustion, estoppel)?
No NuVasive response, invalidity contentions, noninfringement positions, or defenses (statutory or equitable) are provided. Defense structure typically determines the value of the case and expected settlement range, but the factual record is missing.
How does NuVasive contest infringement (product feature mapping)?
No mapping exists in the provided input.
What invalidity grounds are raised (anticipation, obviousness, indefiniteness)?
No invalidity grounds are provided.
Has there been a Paragraph IV or ANDA/Biologics exclusivity challenge in 1:21-cv-00053?
The case is between “Jackson, M.D.” and NuVasive, Inc. NuVasive is a medical device company; there is no information indicating FDA exclusivity, Orange Book, Paragraph IV, or Hatch-Waxman mechanisms. The provided input does not include any regulatory exclusivity or drug-specific listing data.
What is the FDA regulatory context?
No FDA pathway or product classification is included.
Is this an FDA device action case, or a purely patent dispute?
No procedural or regulatory linkage is provided.
How does this litigation affect NuVasive’s product roadmap and freedom to operate?
A litigation impact analysis requires at least: (1) asserted patents and claim scope, (2) the allegedly infringing NuVasive product lines, (3) case stage and any injunctive relief risk, and (4) any settlement terms. None of those inputs are provided.
What licensing leverage does the asserted portfolio create?
No portfolio details are provided.
What design-around or indemnity implications follow?
No infringement or invalidity findings are provided.
What settlement or injunction risk exists for NuVasive?
Settlement posture depends on docket events (Markman outcomes, early dismissal, summary judgment outcomes), and injunction risk depends on likelihood of infringement and validity plus irreparable harm findings. None of those are provided.
Have there been settlement agreements?
No settlement information is included.
Has any court issued claim construction or summary judgment orders?
No orders are included.
Key takeaways
- The provided input does not include asserted patents, infringement allegations, docket history, or outcomes for Jackson, M.D. v. NuVasive, Inc., No. 1:21-cv-00053.
- Without those litigation facts, a complete and accurate infringement/invalidity summary and business impact analysis cannot be produced.
FAQs
-
What court rules and scheduling orders govern 1:21-cv-00053?
Not determinable from the provided input.
-
Which NuVasive products are accused of infringement in Jackson, M.D. v. NuVasive?
Not determinable from the provided input.
-
What is the status of any claim construction (Markman) order in 1:21-cv-00053?
Not determinable from the provided input.
-
Are any patents asserted in this case being challenged at the PTAB?
Not determinable from the provided input.
-
Does this case seek injunctive relief or only damages?
Not determinable from the provided input.
References
- (No sources were provided in the prompt.)
